The increased PPAR-α and the downstream primary regulator enzyme and transporter protein CPT1A in the NAFLD animals could be an adaptive response to the excessive lipid input resulting from the HFD-C administration to enhance the FFA entry into the cells for beta-oxidation [31, 32]. The gene discussed is CPT1A; the disease is metabolic dysfunction-associated steatotic liver disease.